🚨 Negative results from KEYNOTE-866 at #ESMO26.

Juan Pablo Rojas Manrique· @JPRojasUroOnco · X·2026-10-23 19:44· 2 天前评分70

正文 · 原文

Perioperative pembrolizumab added to neoadjuvant gemcitabine/cisplatin failed to significantly improve event-free survival in muscle-invasive bladder cancer (HR 0.88; 95% CI 0.71–1.10; P=0.1366).

#BladderCancer

166 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study

https://esmocongress.esmo.org

来源：Juan Pablo Rojas Manrique · x.com